Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176

Detalles Bibliográficos
Autores principales: Auclin, Edouard, Mezquita, Laura, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307040/
https://www.ncbi.nlm.nih.gov/pubmed/34298837
http://dx.doi.org/10.3390/cancers13143624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307040/
https://www.ncbi.nlm.nih.gov/pubmed/34298837
http://dx.doi.org/10.3390/cancers13143624

Ejemplares similares